The results of pre-clinical in-vivo research studies suggested that Clearmind’s drug candidate MEAI may be effective in the treatment of substance addiction without interrupting the natural reward process Tel Aviv, Israel / Vancouver, Canada, Jan. 17, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on…
Source